At InflaRx, we are a team of internationally recognized researchers and clinicians who have dedicated our careers to translating discoveries and expertise into new therapeutic concepts for clinical application.
Visit clinicaltrials.gov to learn more about study participation including eligibility, risks and benefits participation, the informed consent process, questions to ask when considering study participation.
Learn more about InflaRx-sponsored clinical trials below:
PH.IIB SHINE: Efficacy and Safety Study of IFX-1 in Patients with Moderate to Severe Hidradenitis Suppurativa (HS)
PH.II(a): Studying Complement Inhibition in Patients with Moderate to Severe Hidradenitis Suppurativa
PH.II(a): Exploratory Study of IFX-1 in Subjects With Pyoderma Gangrenosum
PH.II/III PANAMO: Randomized, Controlled Study of IFX-1 in Patients with Severe COVID-19 Pneumonia
PH.II IXCHANGE: Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis.
PH.II IXPLORE: Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)
PH.II: Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.
PH.II SCIENS: Studying Complement Inhibition in Early, Newly Developing Septic Organ Dysfunction
PH.II CARDIAC: Studying Complement Inhibition in Complex Cardiac Surgery
PH.I: Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29 (formerly IFX-1)
